SITAGLIPTIN PHOSPHATE
| Brand name | SITAGLIPTIN PHOSPHATE |
|---|---|
| Active ingredient | SITAGLIPTIN PHOSPHATE |
| Strength | EQ 25MG BASE |
| Dosage form | TABLET |
| Route | ORAL |
| Modality | Small molecule |
| FDA approval | January 2026 |
| Marketing status | RX |
| Code | Expires |
|---|---|
| PC | November 2026 |
Source: FDA Orange Book, layered on the CliffBio company graph. Cliff dates are the FDA regulatory exclusivity expiry; estimates are projections, not legal advice.